Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06446531 · ClinicalTrials.gov registry record · Phase 1
Prevention of Progression of Prediabetes, Obesity and CV Risk
A Phase 1 study of Cardiovascular Diseases and Pre Diabetes, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06446531 is a Phase 1 study of Cardiovascular Diseases and Pre Diabetes that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 64 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06446531, a Phase 1 study of Cardiovascular Diseases and Pre Diabetes, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Rybelsus Tablet
- DRUG Jardiance 25Mg Tablet
- DRUG Actos
Study Locations (1)
Texas
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06446531
The ClinicalTrials.gov registry entry for NCT06446531 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06446531 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06446531 about?
NCT06446531 is a clinical study titled "Prevention of Progression of Prediabetes, Obesity and CV Risk". The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The st...
What is the current status of trial NCT06446531?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2024-09-11. Estimated completion is 2027-07.
What conditions does trial NCT06446531 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Pre Diabetes, Weight, Body.
What interventions are being tested in trial NCT06446531?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Rybelsus Tablet (DRUG), Jardiance 25Mg Tablet (DRUG), Actos (DRUG).
Who is sponsoring clinical trial NCT06446531?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06446531 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
-
AB-1002 in Patients With Class III Heart Failure
ACTIVE NOT RECRUITING · Phase 1
-
Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
COMPLETED · Phase 1
-
MRI-Guided Balloon Angioplasty to Treat Blood Flow Blockage in the Legs
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.